Uwe Platzbecker, MD, University Clinic Leipzig, Leipzig, Germany, shares his key takeaways from the ASH 2021 annual congress in the field of myelodysplastic syndromes (MDS). Dr Platzbecker highlights the presentation of the novel Molecular International Prognosis Scoring System (IPSS-M) as a notable update. The IPSS-M builds on the currently used revised IPSS (IPSS-R), integrating molecular abnormality data to improve risk stratification. Dr Platzbecker comments that the consideration of clinical, cytogenetic, and genetic parameters in this new system make it a refined tool for prognostication. Dr Platzbecker also comments on MDS clinical trial data, including the use of azacitidine-venetoclax, novel triplet therapy, and pevonedistat plus azacitidine in the PANTHER trial (NCT03268954). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Speaker: Uwe Platzbecker Institution: University Clinic Leipzig Event: ASH 2021 Format: Interview Subject: Myelodysplastic Syndromes Field: Treatment Field: Trial Updates Field: Diagnosis Medicines: Azacitidine Medicines: Venetoclax Medicines: Pevonedistat Medicines: Magrolimab Medicines: Antibodies Field: Immuno-Oncology Trial: PANTHER prognostication IPSS-M genetics Trial: VERONA NCT03268954
0 Comments